NewAmsterdam Pharma Reports Director/Officer Changes
Ticker: NAMSW · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1936258
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: NAMS
TL;DR
NewAmsterdam Pharma (NAMS) filed an 8-K for director/officer changes and compensation.
AI Summary
On April 15, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report detailing changes in its board of directors and officers, including the election of new directors and the appointment of certain officers. The filing also addresses compensatory arrangements for these officers and includes financial statements and exhibits. The company, formerly known as NewAmsterdam Pharma Co B.V., changed its name on July 1, 2022.
Why It Matters
Changes in a company's leadership and board can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance updates and does not appear to involve significant financial or operational risks.
Key Players & Entities
- NewAmsterdam Pharma Company N.V. (company) — Registrant
- NewAmsterdam Pharma Co B.V. (company) — Former company name
- July 1, 2022 (date) — Date of name change
- April 15, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors and officer positions?
The filing indicates the departure of directors, election of new directors, and appointment of certain officers, along with details on their compensatory arrangements.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on April 15, 2025.
What was the former name of NewAmsterdam Pharma Company N.V. and when did the name change occur?
The former name was NewAmsterdam Pharma Co B.V., and the name change occurred on July 1, 2022.
What are the main items covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements, Regulation FD disclosure, and financial statements and exhibits.
Where is NewAmsterdam Pharma Company N.V. incorporated and what is its fiscal year end?
The company is incorporated in The Netherlands, and its fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding NewAmsterdam Pharma Co N.V. (NAMSW).